Insight

Jan 6, 2025, 09:48

Amy Moore: PD-1/VEGF combos are a strategy to watch in lung cancer

Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a post on LinkedIn about a recent paper by Keiju Aokage et al. published in Clinical Cancer Research:

“As the field moves to tackle early-stage lung cancer, PD-1/VEGF combos are a strategy to watch in their various forms. The addition of angiogenesis inhibitors may enhance the activity of immune checkpoint inhibitors.”

“Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)”

Authors: Keiju Aokage, Shohei Koyama, Shogo Kumagai, Norihiko Ikeda, Masahiro Tsuboi et al.

More posts featuring Amy Moore.

Dr. Amy C. Moore is the Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation. She previously served as the Director of Science and Research at the Addario Lung Cancer Medical Institute (ALCMI).

She has published peer-reviewed papers on virology, cancer, and biomarker testing in NSCLC. Dr. Moore is also an expert on COVID-19’s impact on lung cancer and serves on several advisory boards.

Amy Moore cancer Immune Checkpoint Inhibitors Keiju Aokage Lung cancer Masahiro Tsuboi Norihiko Ikeda NSCLC OncoDaily Oncology PD-1/VEGF Shogo Kumagai Shohei Koyama

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

New FDA PreCheck Program to Boost U.S. Drug Manufacturing

Vinay Prasad Rejoins FDA Days After Exit